Dr. Foster’s current research focuses on immunotherapy for pediatric solid and brain tumors. Specifically she is investigating chimeric antigen receptor (CAR) T cell therapy for neuroblastoma, high-grade gliomas, medulloblastomas, diffuse intrinsic pontine gliomas, and other brain tumors. The goals of her research are to develop pre-clinical CAR T cells for translation into clinical trials to help these devastating tumors.
Dr. Grupp develops and conducts preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. Dr. Grupp leads most CTL019 (CD19 CAR) clinical trials, and his colleagues are the global leaders in highly active CAR T cell therapy.
Dr. Maris investigates the molecular and genetic mechanisms contributing to the development and progression of neuroblastoma, a common childhood cancer. He also aims to develop new molecular diagnostic tests and less toxic, targeted therapies to treat relapsed or refractory neuroblastoma, including a major effort in immunotherapy discovery and development.
Dr. Barret's research program focuses on immune function of children with cancer. His research involves investigating possible immune deficiencies that result in children developing cancer and developing immune-based therapies for childhood cancer.
Dr. Maude focuses on novel therapies for high-risk and relapsed pediatric acute lymphoblastic leukemia (ALL). She aims to identify new pediatric ALL treatments that are more effective, less toxic, and exhibit fewer side effects than existing cancer therapies.
Dr. Franco researches the molecular basis of the differences between pediatric and adult onset thyroid cancer. She aims to understand how the tumor microenvironment impacts disease progression and response to therapy.
Dr. De Raedt researches pediatric high grade glioma development and aims to understand the involvement of crucial pathways. He investigates pathway interaction, and explores ways to develop therapies through analyzing human tumors, performing cellular studies, and developing accurate mouse models. This allows Dr. De Raedt and his team to perform novel pre-clinical studies that can lead to clinical trials.
Dr. Wolpaw works on inflammatory signaling in childhood solid tumors, particularly neuroblastoma. The hope is that understanding these pathways and how to modify them will allow us to rationally design approaches to enhance the efficacy of immunotherapies.
Dr. Thomas-Tikhonenko has a long-standing interest in the pathobiology of solid and hematopoietic malignancies, in particular lymphomas and leukemias and other cancers driven by MYC overexpression. Within that research space, his studies focus mainly (but not exclusively) on RNA-based regulatory mechanisms, such as microRNAs and alternative mRNA splicing.